Biotechnology company Sinopia Biosciences has received a $2.2 million grant from the National Institute of Dental and Craniofacial Research to advance its oral mucositis research.
This grant builds on its phase I success, where researchers identified a previously unexplored target for oral mucositis treatment, according to Sinopia.
The company aims to leverage its platform, which uses artificial intelligence, machine learning, and multiomics data to find new therapeutic targets.
